INTRODUCTION
The Gram positive bacterium Staphylococcus aureus is a commensal of humans and an important opportunistic pathogen that causes infections in both hospital and community settings (1) . It can cause mild superficial skin infections as well as invasive life-threatening infections such as endocarditis and necrotizing pneumonia (2) . S. aureus infections are aggravated by the ability of the organism to acquire resistance to antimicrobial drugs (3) . Approximately 20% of the human population persistently carry S. aureus in the moist squamous epithelium of their anterior nares, the remainder of the population can carry the organism intermittently (4) . Subjects with S. aureus carriage are at increased risk of infection compared to non-carriers (5) .
Understanding the bacterial surface factors that mediate colonization of the nares is of fundamental importance. A number of staphylococcal cell wall anchored proteins may participate in this process. The surface proteins clumping factor B (ClfB) and iron regulated surface determinant protein A (IsdA) promote adhesion of bacteria to desquamated nasal epithelial cells ex vivo (6, 7) . This correlates with preclinical in vivo studies in rodents where expression of ClfB and IsdA by S. aureus is associated with increased colonization of the nares (8, 9) . Clinically, it has also been demonstrated that ClfB deletion strains are cleared more rapidly from humans compared to isogenic wild type strains (10) . The serine aspartate repeat proteins SdrC and SdrD and the S. aureus surface protein SasG also promote bacterial adhesion to squames cells in vitro (11, 12) but a role for these proteins in colonization of the nares so far has not been reported.
Prevention of nasal carriage by topical administration of the antibiotic mupirocin reduces the risk of infection (13) . Active immunization of mice with recombinant ClfB protein or passive immunization with a monoclonal anti-ClfB antibody reduced experimental colonization (9) suggesting that reduction of colonization should be a desirable endpoint for any human anti-S. aureus vaccination program. Understanding the molecular details of bacterial adhesion to squames and colonization of the nares could lead to novel strategies to reduce carriage and the risk of infection.
ClfB is a member of a family of proteins that are covalently anchored to the cell wall peptidoglycan. Staphylococci can express up to 22 such proteins on their cell surface (14) . Some of the surface proteins promote adhesion to components of the extracellular matrix (e.g. collagen, fibrinogen, fibronectin) during infection and are called MSCRAMMS (microbial surface components recognizing adhesive matrix molecules) (14) . Thus the MSCRAMM, SdrG of S.epidermidis binds to the fibrinogen (Fg) -chain (15, 16) and ClfA of S. aureus binds to the Fg -chain (17, 18) . CNA binds to the collagen triple helix (19, 20) . Functional redundancy is a common theme with several surface proteins capable of binding to fibrinogen. Also, dual or multiple binding specificities are often observed. The aforementioned ClfB binds to the -chain of fibrinogen (21) as well as to cytokeratin 10 (22) . Fibronectin binding proteins FnBPA and FnBPB bind to fibrinogen (23) and elastin (24) as well as the ligand after which they are named, fibronectin (25, 26) .
Members of the ClfA-Sdr family of MSCRAMMS have a similar domain organization and protein folding characteristics (14) (Fig. 1A) . A signal sequence is located at the N-terminus, which is cleaved during protein secretion. The Nterminus of the mature surface-exposed protein comprises the ligand-binding A region which is composed of three sub-domains N1, N2 and N3. Following the A region are one or two repeated regions. Some members have between 2-5 separately folded B repeat units (27) , which form rigid rod-like structures. This is followed by the flexible repeats of the dipeptide serine-aspartate. Both repeat segments are believed to facilitate extension of the ligand-binding region from the cell surface. The C-terminus comprises a cell wallspanning region, an LPXTG sequence, which is cleaved by the trans-peptidase sortase during covalent anchorage of the protein to the cell wall peptidoglycan (28), a hydrophobic membrane-spanning domain and positively charged residues at the extreme C-terminus. The last two segments are cleaved from the mature protein during secretion and anchoring.
The interaction between the N2N3 subdomains of the A region of SdrG, and its ligand, has been studied in detail at the submolecular level (16) . Crystal structures of the apo form of SdrG and of a complex of the interacting Fg -chain peptide bound to SdrG revealed the so-called "dock, lock, latch" (DLL) mechanism of binding (16) . A cartoon describing the DLL mechanism is shown in supplementary figure S1. The Fg -chain peptide docks into a ligand-binding trench located between subdomains N2 and N3 through an anti-parallel -strand complementation of the G-strand of N3. Subsequently the peptide is covered and locked in place by redirection of the Cterminal extension of N3. C-terminal of the lock segment the N3 extension forms a latch by -strand complementation with a -strand exposed in a trench within subdomain N2. A closed structure of the apo form of the SdrG N2N3 segment, containing an engineered disulfide bond to covalently keep the latch in place, failed to bind the ligand peptide (29) . Thus the ligand can only bind to an open form of the apo-protein where the latching sequence is free. More recent analysis (30) showed that ClfA binds the Fg -chain peptide by a variation of the DLL mechanism whereby the ligand peptide forms a parallel -strand with the G-strand of the N3 module of the MSCRAMM and slide into the binding trench of a stabilized locked form.
The A domain of ClfB binds to two seemingly disparate ligands, K10 and Fg (21, 31) . The binding site within K10 was mapped to the Cterminal Tyr-(Gly-Ser) n loop region (22) . One loop YGGGSSGGGSSGGGH segment was studied in detail. The binding site for ClfB in the -chain of Fg was mapped to repeat 5 of the flexible region of the C domain (GSWNSGSSGTGSTGNQ) a segment that might form a loop similar to those in the K10 tail region (31) .
In this study we have investigated the structural basis for the interaction of ClfB with synthetic peptides corresponding to the identified binding sites in Fg -chain and K10, respectively. We show that the N2N3 segment of ClfB folds into two subdomains comprising DEv-IgG folds (32) , similar to SdrG and ClfA and that the two ligands bind to the same region of the binding trench. Both ligand peptides form parallel -strand complementations with a -strand (strand G) in N3.. We show that several residues in ClfB are important for binding to both ligands and identify an interactive motif GSSGXG found in both ligands.. However, the MSCRAMM residues engaged by residues in the common motif differ somewhat between the two ligands.
In addition ClfB interacts with several Fg specific residues outside the common motif suggesting that the identified motif constitutes only part of the ClfB binding sites.
EXPERIMENTAL PROCEDURES
Bacteria and Growth Conditions E. coli strains XL-1 Blue and TOPP3 (Stratagene, La Jolla, CA) were used as hosts for cloning and expression, respectively. Cells were grown in LB broth containing 100 μg/ml ampicillin.
DNA Manipulation
DNA restriction enzymes were purchased from New England Biolabs and used according to the manufacturer instructions. DNA segments encoding the N2N3 domain of ClfB (Accession Numbers: YP_001333563.1) or its corresponding truncated versions were amplified by PCR using S. aureus Newman chromosomal DNA as template. Enzyme restriction sites BamHI and HindIII were incorporated at the 5' ends of the primers to facilitate cloning in pQE30 expression plasmid (Qiagen, Chatsworth, CA). Site directed mutagenesis was performed using the pQE30 ClfB 212-542 plasmid as template. The introduction of specific mutations was performed using primers listed in Table 3 . The resulting PCR mixtures were digested using DpnI for 1 h at 37°C to eliminate parental DNA and transformed into E. coli XL-1 Blue competent cells. The presence of appropriate DNA sequences were confirmed by Sanger sequencing using specific forward and reverse pQE30 sequencing primers at the Baylor College of Medicine DNA Core Facility, Houston, TX.
Expression and Purification of Recombinant Proteins
Expression and purification of recombinant MSCRAMM proteins were performed as described previously for SdrC (33) . Briefly, recombinant proteins were expressed from appropriate plasmids in E. coli TOPP3. Overnight starter cultures were diluted 1:50 in LB containing ampicillin (100 g/ml) and incubated with shaking until the culture reached OD 600 0.6 -0.8. Recombinant protein expression was induced by addition of 0.1 mM IPTG (final concentration) and continued during 4 hours incubation. Bacterial cells were harvested by centrifugation, resuspended in PBS and frozen at -80°C. Recombinant proteins were purified from cell lysates by Ni 2+ affinity and ion exchange chromatography.
Solid phase assay
Immulon 4BH plates were coated with 1 g of Fg (obtained from ChromogenixAB) or recombinant K10 (produced as described in (22)). Coated wells were blocked for 1 hour at room temperature with 3% BSA in 0.5% Tween-TBS buffer. Increasing concentrations of ClfB recombinant proteins were added to the wells and incubated for 1 hour at room temperature. The wells were washed and bound ClfB protein was detected with a polyclonal antibody (1:3000) against ClfB N2N3 (H.T.I. BioProducts) followed by an antirabbit HRP-labeled antibody (1:5000) (BioRad Labs, Hercules, CA). HRP dependent color development using SigmaFast OPD (Sigma, St. Louis, MO) as a substrate was monitored using a microtiter plate reader (Molecular Devices) at 450 nm. Data presented represent the mean ± SD of three independent experiments performed in triplicate. The binding was analyzed by nonlinear regression for one binding site (GraphPad Prism). The relative binding was calculated as percent of the wild type protein binding which was considered 100%.
Crystallization.

Apo-ClfB 199-542
Initially a droplet of 2μl of rClfB N123 at 9mg/ml and 2μl 0.7 M sodium formate was equilibrated against a reservoir containing 1 by guest on October 5, 2017 http://www.jbc.org/ Downloaded from ml of 1.44 M sodium citrate. The crystals belong to tetragonal P4 3 2 1 2 space group. Electronspray ionization mass spectrometry (EI-MS) measurements on the dissolved crystals revealed that the rClfB N123 (59 kDa) had broken down to a molecular weight of 38 kDa and the N-terminal sequencing revealed Ala199 as the N-terminus. Subsequently for the structural and biochemical ligand binding studies recombinant ClfB 212-542 was used. ClfB:ligand peptide complexes. Crystals of the ClfB:K-10 peptide complex was generated by soaking apo crystals of ClfB 212-542 in the peptide solution. Apo-crystals of ClfB 212-542 were first grown by mixing 1.5 l of protein solution with 1 l of reservoir solution containing 0.9 M sodium citrate/90 mM imidazole pH 8.0. These apo-ClfB 212-542 crystals were soaked in 1 mM of K-10 peptide containing the reservoir solution for 5 hours at 20°C. Large chunky apo-ClfB 212-542 crystals cracked after a few minutes of soaking but a large piece of crystal was used for the X-ray data collection. A Similar soaking method was adopted to obtain the co-crystal of 16 residues Fg -chain peptide with ClfB 212-542 .
X-ray data collection, Structure Solution and refinement.
Diffraction data to 2.45 Å resolution was collected on a R-axis IV image plate detector mounted on a Rigaku rotating-anode generator. Data were collected over 120° at a distance of 200 mm with 1° oscillations. Data statistics are reported in Table 1 . The crystal structure was solved by the MIR method. Four derivatives, trimethyl lead acetate (TMLA), Ethyl mercurythiosalicylate (EMTS), uranyl aceteate (UA) and Mersalyl acid (MA) were identified by difference patterson analysis using the program XTALVIEW (34) . The TMLA and UA had two sites each whereas EMTS and MA had one. Refinement of heavy atom derivatives and subsequent phase calculations were performed using the program SOLVE (35) . An initial 3.5 Å electron density map clearly defined the solvent and revealed well-connected main chain densities. The initial CA trace was made using the baton mode in O. Side chains were incorporated into the model and further refinements were done using CNS (36) . The initial R-facror/Rfree of the fully built model with side chains was 33.9/41.0 %. The model building was performed using O in conjunctions with Oops. Maximum likelihood refinement and bulk solvent correction were done with CNS (36) . The final model has 99% of the residues in the allowed region of the Ramachandran plot. Three residues Val204, Asn207, and Thr213 are in the disallowed region. However, all three with higher temperature factors and weak electron density are in the flexible region of the N-terminus of the protein.
ClfB 212-542 :K10 peptide and ClfB 212-542 :Fgchain peptide
Crystals soaked in the peptide solution were flash frozen with a stabilizing solution containing 25% glycerol. Diffraction data were measured on Rigaku R-Axis IV ++ detector. A total of 120 frames were collected at a detector distance of 150 mm with 1° oscillation for the ClfB:K10 peptide complex and 180 frames for the ClfB:Fg -chain peptide complex. Data were indexed, integrated and scaled using HKL2000 (37) . The co-crystals of K10 and Fg -chain peptides diffracted to 2.6 and 2.5 Å resolution respectively and the data statistics are listed in Table 1 . The structure was solved by molecular replacement (MR) with the program PHASER (38) using apo-ClfB as search model. After obtaining the structure solution of ClfB using MR, it was subjected to simulated annealing at 1000 K using CNS (36) . Electron density maps calculated at this point clearly showed electron density for peptide molecules in the binding trench between the N2 and N3 domains.
Model building and refinement were performed using the program COOT (39) . After several cycles of refinement using CNS (36), rebuilding and adding water using COOT (39), a few cycles of refinement using Refmac5 (40) . In the ClfB:K10 peptide complex, electron density was not observed for the N-terminal peptide residues Tyr473, Gly474, Gly475 and Gly476. Electron density for the side chain of Ser477 was not observed but backbone atoms of Ser 477 could be modeled. The numbering refers to residues in the Human K10. The Cterminal residues of ClfB from 532 to 542 in the ClfB:K10 peptide complex and residues 529 to 542 in the ClfB:Fg -chain peptide complex were not modeled due to lack of detected electron density. In the ClfB:Fgchain complex, additional density were observed for the three modeled terminal residues 526-528 and therefore modeled as alternate conformation. The ClfB:K10 peptide and ClfB-Fg -chain peptide structures, respectively, were refined to final R-factors of 18.1 and 17.8 % and R-free values of 21.8 and 20.7%. Stereochemical quality of the model was validated using PROCHECK (41) and figures were made using RIBBONS (42) and PyMOL.
RESULTS
Crystal structure of apo-ClfBN2N3 199-542 Domain
Crystals of ClfB 199-542 were obtained by the hanging drop method using the conditions described in the Experimental section. The crystal structure was determined at 2.45 Å resolution by the Multiple Isomorphous Replacement, (MIR) method. The recombinant ClfB 199-542 crystallized in the tetragonal space group P4 3 2 1 2 that consists of eight asymmetric units. The crystallographic and refinement statistics are presented in Table 1 . ClfB 199-542 folded into two domains, each adopting the DE-variant of the IgG fold in a similar fashion to ClfA and SdrG (Fig.  1B) (16, 32) . The structure of the N2 and N3 subdomains superposes with each other with a rms deviation of 0.95 Å. The inter-domain orientation of the N2-N3 subdomains is similar to that observed in the SdrG apoprotein and in the ClfA-Fg -peptide complex (16, 18) . During model building, the MIR map at 3 Å resolution showed a section of continuous electron density between the D and E strands of the N2 domain that could not be connected to any other part of the molecule. Similarly, an additional electron density present adjacent to the strand G of the N3 domain could not be linked to any part of the structural model. During the final stages of refinement, the two additional densities were identified as extensions of the N-and the Ctermini, respectively, of the symmetry related molecules. The C-terminal of one molecule extends out and interacts with the N2 domain of a crystallographic two-fold related molecule (Fig. 1C) . The structure revealed that the Nterminal residues 199-211 do not belong to the N2 sub-domain thus refining the ligandbinding region to residues 212-542 (Fig. 1C) . Subsequent studies were performed using recombinant ClfBN2N3 212-542 .
The Structure of ClfBN2N3 212-542 in complex with a cytokeratin 10 derived peptide We determined the structure of the ClfB:K10 peptide complex at 2.6 Å resolution by the molecular replacement (MR) method using the ClfB apo-structure as the search model. The co-crystal was obtained by soaking newly obtained apo-ClfB 212-542 crystals in a stabilizing solution containing a synthetic peptide corresponding to the identified ClfB binding site in cytokeratin 10. Similar to SdrG-and ClfA-ligand complexes (16, 18) , the K10 peptide binds in the trench formed between the N2 and N3 sub-domains of the Aregion (Fig. 2A) . The 15 amino acid peptide corresponds to residues Tyr473 to His487 of human K10. The final refined model contained 11 out of the 15 amino acids of the peptide ligand. Electron densities were not observed for amino acids Tyr473, Gly474, Gly475 and Gly476 of the peptide and the C-terminal residues 532-542 of ClfB.
The interaction between the ClfB 212-542 and the K10 peptide buries a total accessible surface area of 1463Å 2 . Six of the eleven K10 residues that interact with ClfB are glycines anchored by the aromatic residues Phe520 and Trp522 in the N3 sub-domain as well as Phe328 in the N2 sub-domain (Fig. 2B ). ClfB's Phe520 and Phe328 anchor Gly479 and Gly486, respectively and both Gly480 and Gly481 are anchored by Trp522. Tryptophan flourescence experiments performed in an earlier study (22) indicated that Trp522 and/or Trp405 were by guest on October 5, 2017 http://www.jbc.org/ Downloaded from involved in binding to K10. The co-crystal structure confirms that Trp522, but not Trp405, is involved in anchoring the K10 peptide. The stretch of residues between Ser478 and Gly484 in the K10 peptide are involved in backbone hydrogen bonding interactions ( -sheet complementation) with strand G of the N3 sub-domain of ClfB ( Fig.  2A and 2C , Table 2 ). The backbone atoms of Asn268 and Asp270 from the N2 domain interact with the backbone of the K10 peptide residues Gly485 and His487 (Fig 2C, Table 2 ). In addition to the -sheet complementation, several side-chain to side-chain/main-chain hydrogen bonding interactions are involved in anchoring the ligand peptide. Side-chains of Gln377 and Ser236 of ClfB are involved in hydrogen bonding interactions with the O atoms of Ser482 and Ser483 of the K10 peptide (Fig. 2B) . Hydrogen bonding interactions were also observed between Asp270 and the main-chain nitrogen of Gly485, Gln235 and the main-chain carbonyl oxygen of Gly481 and between Tyr273 and the main-chain carbonyl oxygen of His 487 (Fig. 2B) .
The structure of ClfB in complex with a Fg -chain peptide and comparison with the ClfB:K10 peptide complex Similar to the ClfB:K10 peptide complex, the ClfB:Fg -chain peptide complex was obtained by soaking the apo-ClfB (212-542) crystal in a solution of ligand peptide. Electron densities were not observed for C terminal residues 529-542 of ClfB. The Fg -chain peptide bound in the trench formed between the N2 and N3 subdomains of ClfB with the same orientation as that of the K10 peptide (Fig. 3A) . ClfB binds to its ligands by making parallel -sheet interactions with the N3 subdomain. The 16-mer peptide contains residues from Gly 332 to Gln347 (GSWNSGSSGTGSTGNQ) of the -chain of human Fg (Fig. 4A) . The final refined model contains electron densities only for the last 12 C-terminal peptide residues. Unlike other MSCRAMM-ligand complexes for which the structures have been determined, the Nterminal residues of the Fg -chain peptide Trp334, Asn335 and Ser336 do not participate in -sheet complementation with the G strand of the N3 domain but rather swing away from the G strand (Fig. 3A) . As a result the -strand complementation observed in the ClfB:Fg peptide complex is shorter compared to the ClfB:K10 peptide complex. The interaction between the ClfB 212-542 and the Fg -chain peptide buries a total accessible surface area of 1579Å
2 .
An alignment of the structure-based superposition of the ligand sequence of ClfB is shown in figure 4 . The positions of the residues occupying the binding sites in the MSCRAMMS were designated position 0-12 from the N-terminus. Both ligand peptides K10 and Fg have an identical segment (GSSGXG) at positions 4-7 and a G in position 9 and these residues largely engage the same residues in ClfB. However, there are significant differences (Figs. 2-5 ). Gly337 and Ser338 at positions 4 and 5 (Fig. 3B, Table 2 ) in the ClfB-Fg -chain peptide complex deviate from the corresponding positions in the ClfB:K10 peptide complex due to a kink observed in the N-terminus of the Fg -chain peptide ( Fig. 3B and 4 ). This deviation in the relative positions of the three N-terminal residues of the peptide results in a weaker interaction with the backbone atoms at position 2 of the Fg -chain peptide ( Fig. 3A  and 3B ). In addition, in the ClfB:Fg -chain peptide complex, Ser338 at position 5 makes contact only with Gln377 of ClfB compared to bifurcated hydrogen bond with both Trp522 and Q377 by Ser482 of K10 (Fig. 3B , Table  2 ). Similar to the ClfB:K10 peptide complex, the conserved Gly343 residue at position 9 of the Fg -chain peptide (Fig. 4 and 3B ) interacts with the hydrophobic side chain of Phe328. The hydrogen bonds between the residues Asp270, Gln377 and Tyr273 of ClfB with the backbone atoms of the two ligand peptides are also a common feature observed in both the complexes (Fig. 3B , Table 2 ). In addition to these interactions, Thr residues at position 8 and 11 interact in unique ways with Asn238 and Thr383 in the ClfB:Fg -chain peptide complex (Fig. 3B , Table 2 ).
Comparison of MSCRAMM:ligand complexes
The N2N3 subdomains of ClfB and ClfA as found in their respective peptide complexes superimpose with an rms deviation of 1.8 Å and bind their corresponding peptide ligands in the same orientation (Fig. 5A) . In contrast to the S. epidermidis SdrG Fg -chain peptide, which makes an anti-parallel -sheet complementation with the N3 sub-domain, the ClfA and ClfB ligands adopt a parallel -sheet complementation. The key difference between ClfA and ClfB is that ClfA binds to the Cterminus of the Fg -chain whereas ClfB binds to the Fg -chain at a site that is flanked by many residues on either side of the binding region (16 The identified ligands of ClfA and ClfB show some intriguing similarities even though the two MSCRAMMs exhibit only 25% sequence identity and bind different segments in different polypeptides of Fg and only ClfB binds CK-10.. Three Gly residues in K10 and the Fg -chain are conserved at positions 3, 4 and 9 and makes similar interactions with ClfB and ClfA, respectively. The Gly residues in position 4 and 9 are also conserved in thechain peptide bound by ClfB. The corresponding amino acids in the MSCRAMMs that anchor these ligand residues are conserved in ClfA and ClfB. The aromatic amino acid Trp523 (ClfA) that anchors the conserved Gly ligand residue at positions 3 and 4 is also found in ClfB as Trp522. Phe328 in ClfB plays the role of ClfA Tyr338 in anchoring the conserved Gly at position 9 ( Fig. 4 and 5B). The polar residue Ser482 at position 5 in the K10 peptide is replaced by a hydrophobic residue, Ala405, in the Fg -chain derived peptide. This amino acid difference is accommodated by Gln377 (Thr383 in ClfA), which swings towards the ligand and makes a hydrogen bonding interaction with Ser482 at position 5 ( Fig. 4 and Fig. 5B) . Similarly, at position 6 Ser483 residue in the K10 peptide is replaced by Lys406 in the Fg -chain peptide and its binding is accommodated by the Ser236 of ClfB (Fig. 4 and Fig. 5B) . Comparison of the two structures suggests that a few amino acid variations in the MSCRAMM binding site could alter the binding specificity of the ligand.
Investigation of ClfB binding mechanisms by analyzing mutants
The structure of ClfB 212-542 in complex with synthetic peptides mimicking the MSCRAMM binding-sites in Fg -chain and K10 showed that both ligands dock in the binding trench formed between the N2 and N3 sub-domains. However, the complexes analyzed were obtained by soaking crystals of the apo form of ClfB 212-542 in solutions containing short peptides from the two ligands. To evaluate if biding of the intact ligand proteins involved the identified interactions with the peptides we used a mutational approach. Mutated ClfB proteins containing truncations or selected amino acid substitutions were generated, purified and tested for binding to immobilized intact Fg and K10 in solid phase binding assays. The C-terminal residues following the G' strand of MSCRAMMs makes direct interaction with the ligand and locks the ligand in place. Truncation of amino acid residues 526-542 ablated ClfB binding to both Fg and K10 suggesting that one or more of the residues in positions Asn526, Val527, Val528 are critical for ClfB interaction with both ligands (Fig. 6A and 6B ). These residues belong to the Lock region that makes direct interaction with the main-chain atoms of the ligand and therefore are crucial for ligand binding. The N2, N3 sub-domains and the reoriented lock region in the complex almost completely bury the C-terminal region of the ligand peptide. The ClfB Asn526 residue points inward and lines the binding pocket. Replacing Asn with a polar but bulkier Gln residue would potentially hinder the proper locking event. This hypothesis was tested by substituting Asn526 in ClfB with Gln, which resulted in a greatly reduced binding of the MSCRAMM to both ligands. In addition substitution of four other residues that participate in the interaction of ClfB with both ligands (Q 235 A, S 236 Q, F 328 A and W 522 V) completely eliminated the binding of ClfB to both Fg and K10, whereas the D 270 E, Q 377 A and F 520 A substitutions reduced the binding to both ligands by 50%. Amino acid residues Asn238 and Thr383 contact only the Fg peptide (Fig. 3B) . Substitution of the two residues with Ala (N 238 A and T 383 A) results in reduced binding to Fg whereas these replacements did not affect K10 binding to ClfB (Fig 6B) .
DISCUSSION
The ability of S. aureus to colonize the host by adhering to desquamated epithelial cells in the nasal vestibule, to bind to plasma proteins and to adhere to the extracellular matrix during invasive infection is mediated by proteins located on the cell surface. A family of structurally related MSCRAMMs forming the Sdr family is involved in these processes. The interaction of these proteins with their specific ligands follows a similar pattern. The ligand docks into a binding cleft formed between two IgG-like folded subdomains located in the A region of the MSCRAMM. Known ligands for ClfA and SdrG are locked in place and the complex is stabilized by a Cterminal extension of the last IgG-like module through direct interaction and a -complementation process involving a strand in the first module. Clumping factor B is a bifunctional adhesin, which has a major role in nasal colonization as well as being able to bind Fg and contribute to the disease process. Since nasal carriage is a risk factor for bloodstream infection ClfB's role in nasal colonization may be of particular importance. Expression of ClfB promotes nasal colonization by binding to K10 molecules that are exposed on the surface of desquamated epithelial cells. Specifically ClfB binds to the repeated Gly/Ser-rich loops found in the C terminal region of the K10 molecule. Similarly, ClfB binds another Gly/Ser rich sequence located in the C terminal part of the Fg -chain. This study presents the crystal structure of apo-ClfB N2N3 as well as ClfB N2N3 in complex with either the Fg -chain derived peptide (GSWNSGSSGTGSTGNQ) or the K10-derived peptide (YGGGSSGGGSSGGGH). In its apo form, the ligand-binding domain of ClfB folds into two IgG-like domains like other crystallized members of the family, SdrG and ClfA. In the apo-protein structure the C-terminal extension of the protein interacts with another ClfB molecule in the crystal. (Fig. 1B) . In addition, we determined the crystal structures of ClfB N2N3 in complex with synthetic peptides corresponding to the identified ClfB binding sites in the Fg -chain and K10, respectively. The crystals of the ClfB:Fg -chain peptide and ClfB:K10 peptide diffracted with 2.4 Å and 2.6 Å, respectively. Although a 15 residue K10-peptide was used, electron densities were observed only for 11 residues. Similarly, only 12 residues out of the 16 residues Fg peptide diffracted in the ClfB:Fg peptide complex. Further analysis revealed that both ligand peptides dock in the binding cleft located between the N2 and N3 subdomains, like previously described SdrG: and ClfA:ligand complexes. We identified a common motif GSSGXG present in the two ligand peptides that interact with ClfB. This motif is fairly common and is found in many mammalian proteins. Thus it is possible that ClfB recognizes additional ligands. The proteins dermokine and plakopilin are particularly interesting as potential ligands since they represent extracellular host proteins and could serve as targets for bacterial adhesins mediating attachment to skin or epithelial surfaces. However, preliminary studies indicate that the affinities of ClfB N2N3 for intact Fg or K10 are significantly higher compared to the corresponding binding site peptides (unpublished) suggesting that residues outside the identified ligand biding mofis in Fg and K10 contribute to the interaction.
To explore if the residues in ClfB shown to interact with the ligand peptides are also important for the binding of the intact protein ligands we used a mutational strategy. The results of these experiments showed that Gln235, Trp522, Ser236 and Phe328 in ClfB that are predicted to make contact with the conserved GSSGXG motif in the ligands are indeed critical for MSCRAMM binding to the intact ligand proteins (Fig. 6C) . Significantly, all ClfB residues that bind the K10 and/or Fg -chain peptides are conserved in a large collection of S. aureus strains representing 48 unique protein variants (43) . Asn238 and Thr383 interact with Fg but not with K10 due to unique residues at the C-terminal region of the Fg ligand peptide.
In addition, we identified that the back bone atoms of Gly521 in the G strand of the ClfB make contact only with the K10-derived peptide due to a kink in the Fg -chain derived peptide, which alters the orientation of the N-terminal part of this ligand. Thus residues in ClfB shown in the crystal structure to engage the two ligand peptides are also important in binding the intact ligand proteins. * R merge = I j -I ⁄ I i ; where I j is the measured and I is the mean intensity of reflection hkl + R free is calculated over 5% of randomly selected reflections not included in the refinement Table 2 : Hydrogen bonds between ClfB and ligand in the complexes* *Hydrogen bonds were detected by Discovery Studio (Accelrys Inc.) using the criterion distance < 3.3 Å between donor and acceptor atoms. 
